FORCONI FRANCESCO
Francesco
Forconi
Ricercatore universitario
Contacts
0577586752
Research
Ultime pubblicazioni:
- Grever, M., Andritsos, L., Anghelina, M., Arons, E., Banerji, V., Barrientos, J., et al. (2024). Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. LEUKEMIA, 38(7) [10.1038/s41375-024-02280-0]. - view more
- Stevenson, F.K., Forconi, F. (2024). The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells. BLOOD, 143(12), 1091-1100 [10.1182/blood.2023022703]. - view more
- Kater, A.P., Arslan, O., Demirkan, F., Herishanu, Y., Ferhanoglu, B., Diaz, M.G., et al. (2024). Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. THE LANCET ONCOLOGY, 25(4), 463-473 [10.1016/S1470-2045(24)00070-6]. - view more
- Moia, R., Dondolin, R., De Propris, M.S., Talotta, D., Mouhssine, S., Perutelli, F., et al. (2023). Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. HEMATOLOGICAL ONCOLOGY, 41(3), 567-570 [10.1002/hon.3080]. - view more
- Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., et al. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. THE LANCET ONCOLOGY, 24(5), 535-552 [10.1016/S1470-2045(23)00144-4]. - view more